Insider filings made public on Wednesday show a mix of concentrated purchases and high-value sales across a range of U.S.-listed companies. The activity spanned packaged foods, frozen foods processing, office furniture manufacturing, aesthetic medical technology, cloud graphics processing, banking, networking equipment and clinical-stage biotech.
Top buys
Conagra Brands Inc (NYSE:CAG) recorded two meaningful director purchases on April 14, 2026. Director Lenny Richard H acquired 25,000 shares of common stock at $14.34 per share, a transaction valued at $358,500. After that purchase Lenny Richard H directly holds 229,340.38 shares of Conagra Brands, which total includes 1,530.56 shares tied to a dividend equivalent reinvestment feature under the company’s Directors' Deferred Compensation Plan. At the time of the filing the stock was trading near its 52-week low of $14.22 and has declined roughly 40% over the last year. InvestingPro commentary included in the filings characterized the stock as appearing undervalued at current levels and highlighted a 9.8% dividend yield.
On the same day, Director John J. Mulligan bought 17,500 shares of Conagra common stock at $14.3087 per share, an outlay of $250,402. After the transaction Mulligan directly owns 20,728 shares. The filing notes the timing of these purchases as the share price traded close to its 52-week low of $14.22, and cited InvestingPro’s Fair Value estimate of $19 that places the name among stocks the platform views as materially undervalued. The company is described as offering a 9.8% dividend yield and as having maintained dividend payments for 51 consecutive years.
Lamb Weston Holdings Inc (NYSE:LW) attracted institutional buying from Jana Partners Management, LP through various managed accounts. A Form 4 filing shows Jana Partners purchased a total of 150,000 shares of common stock for roughly $6.3 million across two tranches. The purchases occurred at prices ranging from $42.12 to $43.19; 100,000 shares were bought on April 13, 2026, and another 50,000 shares were acquired on April 15, 2026. Following these transactions Jana Partners holds 5,398,980 shares of Lamb Weston. The filing places the trades in the context of a stock that has fallen about 31% over the past six months and was trading at $43.17, nearer its 52-week low of $37.62 than to its 52-week high of $67.07.
Virco MFG Corporation (NASDAQ:VIRC) disclosed purchases by Executive Vice President Douglas A. Virtue totaling 16,027 shares of common stock in two acquisitions. On April 14, 2026, Virtue bought 4,349 shares at $6.07 per share; on April 15, 2026, he added 11,678 shares at $6.09 per share. The combined value of these buys was $97,517. After the transactions Virtue directly owns 877,866 shares of Virco. The company’s common stock was trading at $6.09 and the filing included InvestingPro commentary that the stock appears undervalued based on its Fair Value analysis; the noted context also referenced an InvestingPro Tip pointing to aggressive share buybacks by management and that the company remained profitable over the last twelve months. The filing listed a market capitalization of $95.91 million for Virco.
Airsculpt Technologies, Inc (NASDAQ:AIRS) recorded a purchase by a major shareholder and ten percent owner, Jorey Chernett, who acquired 20,000 shares of common stock on April 14, 2026. The shares were purchased at a weighted average price of $2.60, with individual execution prices ranging from $2.59 to $2.61, for a total consideration of $52,000. Following the transaction Chernett directly owns 7,013,761 shares of Airsculpt Technologies. At the time of the filing the stock traded at $2.75 and the filing highlighted the stock’s volatility - a 75% decline over six months contrasted with a year-to-date gain of 32% - and InvestingPro commentary that the stock appeared fairly valued near its Fair Value estimate.
Top sells
CoreWeave, Inc (CRWV) saw several large planned disposals on file. Chief Strategy Officer Brian M. Venturo sold a substantial block of Class A Common Stock on April 13, 2026, via a pre-arranged Rule 10b5-1 trading plan; the sales aggregated to $124.6 million. Prices received for these shares ranged from $104.7966 to $113.8805. The transactions involved shares held indirectly through West Clay Capital LLC and through the Venturo Family GST Exempt Trust dated June 30, 2023. Under the filing West Clay Capital LLC sold 488,394 shares while the Venturo Family GST Exempt Trust sold 224,924 shares. The filings placed the disposals against the backdrop of a CoreWeave share price that has rallied 191% over the past year to $118.69 and a market capitalization stated at $61.6 billion. InvestingPro commentary included in the filings described the stock as appearing overvalued relative to its Fair Value and flagged the stock as being in overbought territory.
CoreWeave filings also show Chief Development Officer Brannin McBee sold 95,000 shares of Class A Common Stock on April 13, 2026, for proceeds of $11.08 million. Those sales took place at prices ranging from $104.66 to $113.94 and were executed under a Rule 10b5-1 trading plan adopted on November 17, 2025. After the sales McBee directly owns 313,732 shares of CoreWeave Class A Common Stock. The filing reiterated that the stock has climbed to $118.69, representing a 191% return over the prior year, and included InvestingPro commentary that the stock appears overvalued at current levels and trades at high revenue and EBITDA multiples.
JPMorgan Chase & Co (NYSE:JPM) Chairman and Chief Executive Officer James Dimon sold 130,488 shares of common stock on April 15, 2026, at a price of $306.557 per share, generating proceeds of approximately $40,002,009. Post-transaction disclosures show Dimon directly owns 1,680,625 shares of JPMorgan Chase common stock. The filing also detailed indirect holdings: 9,005.4963 shares held through a 401(k), 4,209,284 shares held through family trusts, 116,466 shares held through an LLC, and 273,035 shares held by spouse. The filing included Dimon’s statement disclaiming beneficial ownership of the shares held by the LLC except to the extent of any pecuniary interest.
Arista Networks (NASDAQ:ANET) CEO and Chairperson Jayshree Ullal sold 112,812 shares of common stock on April 13, 2026, for total proceeds of $16,934,671. The shares were sold at a weighted average price of $150.1141 in multiple transactions priced between $150.00 and $150.36. After these sales Ullal directly owns 9,917 shares of Arista Networks. The filing also listed Ullal’s indirect holdings: 5,383,207 shares by trust for Child 1, 5,383,207 shares by trust for Child 2, 30,000 shares by Trust for Nephew, 30,000 shares by Trust for Niece, and 18,312,010 shares by Trust. The insider sale came as Arista’s shares traded at $154.33, near a 52-week high of $164.94, after a 111% gain over the past year. InvestingPro commentary included in the filing characterized the stock as appearing overvalued relative to its Fair Value and noted a P/E ratio of 56.
Vor Biopharma Inc (NASDAQ:VOR) disclosed sizable sales by RA Capital Healthcare Fund LP, a ten percent owner and director, which sold a total of 740,789 shares of common stock across several transactions for approximately $11.8 million. The sales were executed over April 13, 2026, to April 15, 2026, at prices ranging from $15.97 to $16.15. Specifically, on April 13 the fund sold 530,610 shares at an average price of $16.15; on April 14 it sold 153,735 shares at an average price of $15.97; and on April 15 it sold 53,644 shares at an average price of $16.01. After these disposals RA Capital Healthcare Fund LP directly holds 3,197,619 shares of Vor Biopharma. The filing noted that VOR stock was trading at $15.60 and had fallen approximately 47% over the past six months; InvestingPro analysis included with the filing described the stock as appearing undervalued based on its Fair Value estimate and noted the company holds more cash than debt on its balance sheet.
Context and market notes
The filings include several valuation notes and situational observations from InvestingPro, ranging from descriptions of apparent undervaluation to warnings of overvaluation. Specific valuations or commentary appearing alongside the Form 4 disclosures include Conagra’s Fair Value estimate of $19 and a 9.8% dividend yield with 51 consecutive years of dividend payments; Virco and Vor Biopharma characterized as appearing undervalued; Airsculpt described as trading near its Fair Value; and CoreWeave and Arista characterized as appearing overvalued with elevated multiples or overbought technical signals. Lamb Weston’s purchases from Jana Partners were contextualized by the company’s 31% six-month decline and the April 13-15 execution dates and price range.
Several of the large sales were carried out under formal trading plans. CoreWeave sales by Brian M. Venturo and by Brannin McBee were both executed under Rule 10b5-1 trading plans, and the filings make clear the sale by Venturo involved indirect holdings disposed of through entities such as West Clay Capital LLC and a family GST Exempt Trust dated June 30, 2023. These procedural details are disclosed alongside the dollar values, share counts and price ranges that define the transactions.
Investor takeaway
Monitoring insider filings provides a direct look at how corporate officers and large holders are transacting in their company's shares. Purchases by directors and major shareholders can signal confidence or a decision to increase exposure, while large sales - particularly those completed under pre-arranged plans - may reflect portfolio management, tax planning, liquidity needs or other non-operational considerations.
It is important to treat insider trading data as one input among many. The filings and accompanying commentary in these disclosures illustrate a range of valuation views and company circumstances. For example, some names in the filings are described by InvestingPro as appearing undervalued and offering meaningful dividend income, while others are characterized as overvalued or trading at high multiples. Insiders may sell for a variety of personal reasons, including portfolio diversification and personal financial planning, and that reality is reflected in several of the disclosed transactions that were completed under 10b5-1 plans.
Investors assessing these disclosures should combine the raw transaction data - dates, prices, share counts, and holdings that appear in the filings - with independent analysis of company fundamentals, valuation metrics and portfolio fit. The filings provide transparency about who bought or sold and at what price, but they do not in themselves establish future outcomes for any listed company.
Disclosure